Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT03010475
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT02994407
- Locations
- 🇷🇸
Novo Nordisk Investigational Site, Novi Sad, Serbia
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Phase 2
Completed
- Conditions
- Hepatobiliary DisordersNon-alcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 320
- Registration Number
- NCT02970942
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
In-market Utilisation of Liraglutide Used for Weight Management in Europe
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 316
- Registration Number
- NCT02967757
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Siena, Italy
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 303
- Registration Number
- NCT02964247
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT02964104
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Phase 3
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 396
- Registration Number
- NCT02963922
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Phase 3
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 282
- Registration Number
- NCT02963935
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Arlington, Virginia, United States
A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7
- Registration Number
- NCT02962440
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
Phase 1
Completed
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT02958085
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath